Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SQOR | Q9Y6N5 | 8/20 | 0.49 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.45 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 6/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 4/20 | 0.41 |
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | GAA | P10253 | 2/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | HPGD | P15428 | 3/20 | 0.39 |
| ▸ | PIM1 | P11309 | 3/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2204237 | 0.96 | SQOR (0.49) | SQORADORA2AADORA1KDM4ENPSR1 | |
| SCHEMBL2203258 | 0.88 | SQOR (0.48) | SQORKDM4ENPSR1RXFP1ALDH1A1 | |
| SCHEMBL2203647 | 0.85 | SQOR (0.43) | SQORADORA2AADORA1KDM4ENPSR1 | |
| SCHEMBL2198128 | 0.85 | GAA (0.48) | SQORADORA2AADORA1KDM4ENPSR1 | |
| SCHEMBL2202236 | 0.82 | GAA (0.44) | SQORADORA2AADORA1KDM4ENPSR1 | |
| SCHEMBL2201824 | 0.82 | SQOR (0.56) | SQORADORA2AADORA1KDM4ENPSR1 | |
| SCHEMBL12510330 | 0.81 | ADORA1 (0.37) | SQORADORA2AADORA1KDM4EALDH1A1 | |
| SCHEMBL2202502 | 0.75 | SQOR (0.43) | SQORADORA2AADORA1KDM4ENPSR1 | |
| SCHEMBL12430361 | 0.73 | SQOR (0.51) | SQORADORA2AADORA1KDM4ENPSR1 | |
| SCHEMBL2201371 | 0.72 | SQOR (0.45) | SQORADORA2AADORA1KDM4ENPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1846402-B1 | 3-AMINO-PYRAZOLO[3,4B]PYRIDINES USED AS INHIBITORS OF PROTEIN TYROSINE KINASES FOR TREATING ANGIOGENIC, HYPERPROLIFERATIVE OR NEURODEGENERATIVE DISEASES | BAYER IP GMBH (DE) | 2014-02-26 | — | — | EP | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-7977325-B2 | 3-amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | BAYER SCHERING PHARMA AG (DE) | 2011-07-12 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | GENESYS CLOUD SERVICES, INC. | 2009-01-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030010-A1 | 3-Amino-pyrazolo[3,4b]pyridines as inhibitors of protein tyrosine kinases, their production and use as pharmaceutical agents | MAP4K2, ABL1, MAP4K3 | SQOR 1563/4885ADORA2A 951/4885ADORA1 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.